|Clinical and Regulatory|
This event is set for a specific date and makes planning easier. However, specific dates may change.
|Disease and Treatment|
|Treatment Name:||Mycapssa™ (octreotide)|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
As we draw closer to our April 15, 2016 Prescription Drug User Fee Act (PDUFA) target date, we are keenly focused on increasing awareness of Chiasma among key constituents while also raising awareness about acromegaly and the unmet needs of patients with this rare disease.